Key Highlights

  • Darkiris (NASDAQ:DKI) rose 55.30% to USD 2.33, with fiscal 2025 Revenue of USD 10.08 million.
  • MIRA Pharmaceuticals (NASDAQ:MIRA) gained 17.59% to USD 0.6089, with cash of USD 3,609,442 on June 30, 2026.
  • Curis (NASDAQ:CRIS) climbed 83.54% to USD 1.3103, with cash of USD 5.1 million on June 30, 2026.
  • T1 Energy (NYSE:TE) rose 10.18% to USD 3.12, with third quarter results due November 12, 2026.
  • ONE Nuclear Energy (NASDAQ:ONEN) advanced 9.56% to USD 1.49, and the company describes about 5 GW of Louisiana projects.

Darkiris (NASDAQ:DKI) (up USD 0.8297, 55.30%): A Hong Kong Mobile Games Penny Stock With No Announcement

Darkiris (NASDAQ:DKI) rose 55.30%, or USD 0.8297, to USD 2.33 in pre-market trading on November 4, 2026, implying a Tuesday close of about USD 1.5003 (calculated). No press release, regulatory filing or Earnings report dated November 2 to November 4, 2026 was identified, so the move appears to be momentum in a thinly traded small cap.

For the fiscal year ended September 30, 2025, revenue was USD 10.08 million, up 27.3%, while net loss was USD 8.64 million, driven mostly by about USD 8.81 million of share based compensation. Cash was USD 1.80 million. As a penny stock it carries volatility, thin Liquidity and dilution risk.

MIRA Pharmaceuticals (NASDAQ:MIRA) (up USD 0.0911, 17.59%): Pipeline Updates but No Fresh Trigger

MIRA Pharmaceuticals (NASDAQ:MIRA) gained USD 0.0911, or 17.59%, to USD 0.6089 in pre-market trading on November 4, 2026, implying a Tuesday close near USD 0.5178 (calculated). No company announcement dated November 2 to November 4, 2026 was identified.

The latest items are pipeline updates. A company press release dated October 22, 2026 described a rat study of oral MIRA-55, and on September 17, 2026 the Ketamir-2 Phase 2a program advanced toward site initiation.

The second quarter 2026 filing showed cash of USD 3,609,442, a net loss of USD 1,208,534 and substantial doubt about going concern. An at-the-market agreement of up to USD 75 million could dilute holders.

Curis (NASDAQ:CRIS) (up USD 0.5964, 83.54%): Biggest Mover on the List Without a Disclosed Event

Curis (NASDAQ:CRIS) rose 83.54%, or USD 0.5964, to USD 1.3103 in pre-market trading on November 4, 2026, implying a Tuesday close of about USD 0.7139 (calculated). No company press release, filing or clinical update dated November 2 to November 4, 2026 was identified, so the jump looks like speculative momentum.

The company's lead candidate, emavusertib, is an oral IRAK4 and FLT3 inhibitor tested in blood cancers, with first TakeAim CLL patient data expected in December 2026. Cash was USD 5.1 million at June 30, 2026, down from USD 15.0 million at March 31, 2026, and a 1-for-20 reverse split took effect on July 2, 2026. An August 2026 offering raised about USD 4.8 million net.

Funds should last only into the fourth quarter of 2026, so dilution is a real risk.

T1 Energy (NYSE:TE) (up USD 0.2883, 10.18%): Earnings Date Approaching After a Rebound

T1 Energy (NYSE:TE) rose 10.18%, or USD 0.2883, to USD 3.12 in pre-market trading on November 4, 2026, against a Tuesday close of about USD 2.83 (calculated). No announcement dated November 2 to November 4, 2026 was identified. The company said on October 27, 2026 that third quarter results will come on November 12, 2026, and the stock had already gained roughly 11% on Tuesday.

Second quarter 2026 net sales were USD 250.1 million versus USD 132.8 million a year earlier, with adjusted EBITDA of USD 10.7 million. Unrestricted cash was USD 79.1 million, against convertible notes of USD 329.0 million.

ONE Nuclear Energy (NASDAQ:ONEN) (up USD 0.1300, 9.56%): New Listing Moving With Nuclear Sentiment

ONE Nuclear Energy (NASDAQ:ONEN) rose 9.56%, or USD 0.13, to USD 1.49 in pre-market trading on November 4, 2026, implying a Tuesday close near USD 1.36 (calculated). No press release or filing dated November 2 to November 4, 2026 was identified, so the move is best read as sector sentiment and momentum.

The company describes about 5 GW of Louisiana projects: Amberjack, targeting up to 1 GW of advanced nuclear, plus Cayman at 2.88 GW and Barracuda at 1.2 GW of Natural Gas with battery storage. None has entered commercial operation, and no quarterly results as a public company were identified. Funding needs could dilute holders, and licensing timelines are long.

Where Things Stand

All five stocks gained in pre-market trading on November 4, 2026 without an identified announcement, and all five trade under USD 5, with dilution as a shared risk. The nearest scheduled markers are the T1 Energy results on November 12, 2026, the Curis CLL data expected in December 2026 and the first Quarterly Report from ONE Nuclear Energy. Gains can fade at the open.